MEDIGARD CEO RESIGNS AFTER FALLOUT

MEDIGARD CEO RESIGNS AFTER FALLOUT

THE chief executive of the ASX-listed medical technology company Medigard (ASX:MGZ) has resigned from the board after seven years with the company.

Peter Emery (pictured) told Gold Coast Business News he has given three months notice following ‘differences with certain board members’.

“The decision to resign is mine and it has not been an easy one. There have been some differences of opinion between myself and other members of the board. I wish the company well.”

While Medigard shares have largely traded sideways on the ASX since 2005, there have also been delays associated with signing a manufacturer and a distributor in the US for its 3ml retractable syringe.

Emery has recently spent time in the US courting potential investors, but says it’s time to try something different and take a ‘long holiday’.

He told Gold Coast Business News last year that Medigard could become a life changer.

“It’s always a good story because the ultimate aim of this is to help health care workers from getting needle stick injuries and this will stop that and there’s a million of them around the world, half of which go unreported. The good side this is that it’s for the benefit of real people, doing real work and they shouldn’t be exposed to some of the risks they are currently exposed to.”

Medigard was floated in 2004 by chairman Don Channer and director Peter Clark.

MGZ shares closed today at 4c.

Get your copy of Gold Coast Business News' annual top companies edition to read about all the city's big players - out in March.

Get our daily business news

Sign up to our free email news updates.

 
Whitefox Recruitment founder Luke Hemmings making strides as a careers leader
Partner Content
After relocating his Canberra-founded company Whitefox Recruitment to the Gold Coast la...
Whitefox Recruitment
Advertisement

Related Stories

ASIC secures its first court win for greenwashing against US giant Vanguard

ASIC secures its first court win for greenwashing against US giant Vanguard

The Australian corporate watchdog has caught out one of the world&r...

Medicinal cannabis group Althea shaves $1.5m from its cost base through staff cutbacks

Medicinal cannabis group Althea shaves $1.5m from its cost base through staff cutbacks

Australian-founded medicinal cannabis company Althea Group (ASX: AG...

Charter Hall snares 15pc stake in Hotel Property Investments for $97m from 360 Capital

Charter Hall snares 15pc stake in Hotel Property Investments for $97m from 360 Capital

Listed funds manager 360 Capital Group (ASX: TGP) has offloaded its...

The party’s over: Splendour in the Grass festival cancelled for 2024

The party’s over: Splendour in the Grass festival cancelled for 2024

Splendour in the Grass, Australia’s largest winter music fest...